Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307) | Zendy

Darya Kizub | Zendy; Jieling Miao | Zendy; Mark M. Schubert | Zendy; Alexander Paterson | Zendy; Mark Clemons | Zendy; Elizabeth Claire Dees | Zendy; James N. Ingle | Zendy; Carla I. Falkson | Zendy; William E. Barlow | Zendy; Gabriel N. Hortobágyi | Zendy; Julie R. Gralow | Zendy

Open Access

Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307)

Author(s) -

Darya Kizub,

Jieling Miao,

Mark M. Schubert,

Alexander Paterson,

Mark Clemons,

Elizabeth Claire Dees,

James N. Ingle,

Carla I. Falkson,

William E. Barlow,

Gabriel N. Hortobágyi,

Julie R. Gralow

Publication year - 2020

Publication title -

supportive care in cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.133

H-Index - 112

eISSN - 1433-7339

pISSN - 0941-4355

DOI - 10.1007/s00520-020-05748-8

Subject(s) - medicine , breast cancer , bisphosphonate , stage (stratigraphy) , oncology , pain medicine , osteonecrosis of the jaw , randomized controlled trial , bisphosphonate associated osteonecrosis of the jaw , nursing research , cancer , prospective cohort study , adjuvant , osteoporosis , anesthesiology , pathology , paleontology , biology

Bisphosphonates reduce bone metastases in postmenopausal women with early-stage breast cancer but carry the risk of bisphosphonate-related osteonecrosis of the jaw (BRONJ). We describe risk factors for BRONJ and compare BRONJ provoked by infection or trauma with spontaneous lesions, which carry a better prognosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research